English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

# BackgroundDespite a large and increasing non-communicable diseases (NCD) burden in Africa, research to inform NCD risk factors, management and outcomes in African populations is limited. # MethodsThe GlaxoSmithKline (GSK) Africa NCD Open Lab targeted outstanding early career African scientists, providing funding and scientific support for projects designed and led by African investigators to increase NCD understanding. Applicants were eligible if based in research institutions/universities in Cameroon, Cote D’Ivoire, Ethiopia, Ghana, The Gambia, Kenya, Malawi, Nigeria, Senegal, Tanzania and Uganda. Proposals in scope addressed cardiovascular disease, oncology, chronic respiratory disease, chronic kidney disease and diabetes, and could examine relationships between these NCDs and infectious diseases, including across the life-course. Ten awards offering up to £100,000 (US$128,500) for two years’ funding were available to cover research project costs. Additionally, GSK offered in-kind scientific support and mentoring throughout the award duration. # ResultsFrom 330 unique proposals submitted, 225 met the eligibility criteria covering cardiovascular disease (25.8%), metabolic disorders (23.1%), oncology (17.8%), respiratory disease (8.9%), chronic kidney disease (7.1%), and ‘other’ (17.3%). The highest number of eligible applications were by researchers from Nigeria (28.4%), Kenya (15.1%), and Uganda (14.2%). Following a multi-stage review process by GSK scientists and an independent Scientific Advisory Board of predominantly African scientists, nine proposals were recommended for funding and collaborative support; three cardiovascular, two respiratory, two chronic kidney disease, and two diabetes. The most common training needs identified by applicants were biostatistics, grants management, clinical trial design, and writing for publication.# ConclusionsBy supporting open innovation research, the GSK Africa NCD Open Lab identified a substantial number of African early career researchers enthusiastic to engage in projects relevant to NCDs. In addition to funding, capacity building efforts are critical to ensure sustainable NCD research and a thriving African research community.

Supporting the next generation of non-communicable disease research leaders in Africa – experience of the GSK Africa NCD Open Lab